Tumor-necrotizing serum production by administration of BCG + Pseudomonas: its application in treatment of fibrosarcoma in mice.
A Pseudomonas aeruginosa (i.v.) treatment (10(8) killed organisms) has shown the capacity to induce the release of tumor-necrotizing factor in the serum of BCG-pretreated mice to the same extent as an LPS treatment. Lower doses of P. aeruginosa (10(7) killed organisms) were applied in BCG-pretreated mice (1 mg given IV 7 days prior to or 1 day after tumor graft) bearing a methylcholanthrene-induced fibrosarcoma. In both cases this combined treatment significantly delayed tumor growth without a toxic side effect.
D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood* / Q000627:therapeutic use; D005354:Fibrosarcoma / Q000628:therapy*; D006023:Glycoproteins / Q000097:blood* / Q000627:therapeutic use; D051379:Mice; D009163:Mycobacterium bovis; D011549:Pseudomonas; D012513:Sarcoma, Experimental / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha
D000970:Antineoplastic Agents; D006023:Glycoproteins; D014409:Tumor Necrosis Factor-alpha